All In Biotech

Drug Trial Radar · NCT03098030

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Dec 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 483 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

483

Actual

Start

Jun 1, 2017

Primary completion

Jan 27, 2020

Study completion Mar 26, 2020

Sponsor

Lead sponsor
United TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-part, multicenter, open-label, randomized study of dinutuximab and irinotecan versus irinotecan alone in subjects with relapsed or refractory small cell lung cancer (SCLC). Part 1 of the study involves intrasubject dose escalation to evaluate the safety and tolerability of dinutuximab in combination with irinotecan. Part 2 of the study is designed to determine whether dinutuximab plus irinotecan prolongs overall survival (OS) compared with irinotecan alone. Subjects in Part 2 will be randomized in a 2:2:1 fashion to 1 of 3 treatment groups: (A) irinotecan; (B) dinutuximab plus irinotecan; or (C) topotecan. Randomization will be stratified by duration of response to prior platinum therapy (relapse-free period \<3 months or ≥3 months).

Conditions

  • Small Cell Lung Cancer

Interventions

  • DinutuximabBiological

    Dinutuximab injection, for intravenous (IV) use

  • IrinotecanDrug

    Irinotecan injection, IV infusion

  • TopotecanDrug

    Topotecan for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 2.5 years

Locations

226 sites in 23 countries. Site status is shown where the registry gives one.

  • Alaska Clinical Research Center

    Anchorage, Alaska

  • Cancer Treatment Centers of America - Western Regional Medical Center

    Goodyear, Arizona

  • Innovative Clinical Research Institute

    Tucson, Arizona

  • Genesis Cancer Center

    Hot Springs, Arkansas

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • VA Palo Alto Health Care System

    Palo Alto, California

  • Olive View - UCLA

    Sylmar, California

  • Innovative Clinical Research Institute

    Whittier, California

  • Hartford Hospital

    Hartford, Connecticut

  • Eastern Connecticut Hematology and Oncology Assoc

    Norwich, Connecticut

  • Alpha Oncology Research LLC

    DeBary, Florida

  • 21st Century Oncology

    Jacksonville, Florida

  • Comprehensive Hematology Oncology

    St. Petersburg, Florida

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Northwest Georgia Oncology Centers, P.C.

    Marietta, Georgia

  • Baptist Health Floyd Cancer Center

    New Albany, Indiana

  • Physicians' Clinic of Iowa Hematology and Oncology

    Cedar Rapids, Iowa

  • Kentucky Cancer Clinic

    Hazard, Kentucky

  • University of Kentucky

    Lexington, Kentucky

  • 21st Century Oncology

    Louisville, Kentucky

  • Cox Health Medical

    Springfield, Missouri

  • Billings Clinic Cancer Center

    Billings, Montana

  • St. Vincent Frontier Cancer Center

    Billings, Montana

  • The University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico

  • UH Cleveland Medical Center

    Cleveland, Ohio

  • Cancer Treatment Centers of America at Southwestern RMC

    Tulsa, Oklahoma

  • Kaiser Permanente Northwest Center for Health Research CRSS

    Portland, Oregon

  • Fox Chase Cancer Center Office of Clinical Research

    Philadelphia, Pennsylvania

  • Cancer Treatment Centers of America at Eastern Regional Medical Center

    Philadelphia, Pennsylvania

  • Charleston Oncology

    Charleston, South Carolina

  • Spartanburg Medical Center/Gibbs Cancer Center and Research Institute

    Spartanburg, South Carolina

  • Prairie Lakes Health Care

    Watertown, South Dakota

  • Center for Biomedical Research

    Knoxville, Tennessee

  • Texas Health Physicians Group

    Arlington, Texas

  • Plano Cancer Institute

    Plano, Texas

  • The University of Texas Health Science Center at Tyler, Office of Clinical Studies

    Tyler, Texas

  • Vista Oncology (Shelton office)

    Shelton, Washington

  • United Hospital Center

    Bridgeport, West Virginia

  • Camden Clark Medical Center / Regional Cancer Center

    Parkersburg, West Virginia

  • University of Wisoncsin - Carbone Cancer Ctr

    Madison, Wisconsin

Showing 40 of 226 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.